ADMA BiologicsADMA +0.55%64 Cyclically Adjusted PS Ratio is 8.30 as of Jul. 07, 2026, which is 66% above its 10-year median of 5.01. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $18.03 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 535 Biotechnology companies, ADMA Biologics ranks worse than 57.76% on this metric.
The historical rank and industry rank for ADMA Biologics's Cyclically Adjusted PS Ratio or its related term are showing as below:
ADMA'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.72 Med: 5.01 Max: 24.86
Current: 8.23
During the past years, ADMA Biologics's highest Cyclically Adjusted PS Ratio was 24.86. The lowest was 1.72. And the median was 5.01.
ADMA's Cyclically Adjusted PS Ratio is ranked worse than 57.76% of 535
companies
in the Biotechnology industry
Industry Median: 5.95
vs ADMA: 8.23
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
ADMA Biologics's adjusted revenue per share data for the three months ended in Mar. 2026 was $0.477. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.11 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
ADMA Biologics (NAS:ADMA) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
ADMA Biologics Cyclically Adjusted PS Ratio Related Terms
ADMA Biologics Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for ADMA Biologics's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA vs ZLAB, HRMY, STOK: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, ADMA Biologics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's Cyclically Adjusted PS Ratio falls into.
ADMA Biologics Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
ADMA Biologics's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 8.30 mean?
ADMA Biologics (ADMA) has a Cyclically Adjusted PS Ratio of 8.30 as of Jul. 07, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on ADMA Biologics and its competitors. This is 66% above median its historical median of 5.01. Over the past decade, ADMA Biologics' Cyclically Adjusted PS Ratio has ranged from 1.72 to 24.86. According to the industry distribution chart, ADMA Biologics ranks #309 out of 535 companies in the Biotechnology industry, placing it in the top 57.8%.
Is ADMA Biologics' Cyclically Adjusted PS Ratio too high?
ADMA Biologics' current Cyclically Adjusted PS Ratio of 8.30 is 66% above median its 10-year median of 5.01. Over the past 10 years, this metric has ranged from a low of 1.72 to a high of 24.86. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.95. ADMA Biologics' value of 8.30 is 39.5% above this industry median. Based on the distribution chart, ADMA Biologics ranks #309 out of 535 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Cyclically Adjusted PS Ratio compare to ZLAB and HRMY?
According to the Biotechnology industry distribution chart, ADMA Biologics ranks #309 out of 535 companies for Cyclically Adjusted PS Ratio. This places ADMA Biologics in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.95. ADMA Biologics' value of 8.30 is 39.5% above this benchmark. Historically, ADMA Biologics' own Cyclically Adjusted PS Ratio has ranged from 1.72 to 24.86 over the past decade. While the company's 10-year median is 5.01 vs. the industry median of 5.95, ADMA Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.95, based on 535 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADMA Biologics's current Cyclically Adjusted PS Ratio of 8.30 is 39.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on ADMA Biologics and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADMA Biologics's current Cyclically Adjusted PS Ratio is 8.30, which is 66% above median its own 10-year median of 5.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.03, compared to a current price of $9.21 — trading 48.9% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 8.30, which is 66% above median its 10-year median of 5.01 and 39.5% above the Biotechnology industry median of 5.95. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Cyclically Adjusted PS Ratio is 8.30 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADMA Biologics (ADMA) Overvalued in 2026?
Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued.
The current stock price of $9.21 is trading 48.9% below its estimated GF Value™ of $18.03.
GuruFocus considers ADMA Biologics to be Significantly Undervalued.
Key valuation signals for ADMA:
Cyclically Adjusted PS Ratio: 8.30 (66% above median its 10-year median of 5.01)
GF Value™: $18.03 vs. price of $9.21 (48.9% below fair value)
Industry Position: 39.5% above the Biotechnology median (#309 of 535)
No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score
Get the complete analysis for ADMA
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADMA has been successfully added to your 
